Loading clinical trials...

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure | Clinical Trials | Clareo Health

COMPLETED

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure

NCT04564378•State University of New York at Buffalo

View on ClinicalTrials.gov

Summary

This study is being done to discover if there is a link between estrogen exposure and the severity of Fuchs Endothelial Corneal Disease. We are trying to understand if the decrease in estrogen levels in post-menopausal women may be a reason why FECD is seen more often in women than men.

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Individuals with FECD grade 1-2/7 (mild) or 5-6/7 (severe) in one or both eyes
•2. Age ≥ 55
•3. Phakic and pseudophakic individuals will be included. Pseudophakic patients must have evidence of routine cataract surgery (posterior chamber intraocular lens in-the-bag without clinical evidence of damage to any intraocular structures).

Exclusion Criteria

•1. Females are excluded if not post-menopause.
•2. Pseudophakic patients with a history of complex cataract surgery or other intraocular surgery (e.g. have an anterior chamber lens, sulcus lens, or poorly positioned posterior chamber lens, aphakia, iris damage, glaucoma surgery) will be excluded due to risk of iatrogenic damage to the corneal endothelium.

Locations (1)

The Ira G. Ross Eye Institute

Buffalo, New York, United States

Key Dates

Start Date

January 17, 2018

Primary Completion Date

April 27, 2023

Completion Date

September 1, 2023

Last Updated

October 1, 2024

Enrollment

ACTUAL participants

Conditions

Fuchs Dystrophy

Interventions

This is an observational study. There is no therapeutic intervention.

OTHER

FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom

NCT06881771

Fuchs DystrophyFuchs' Endothelial Dystrophy+3 more

View study

COMPLETEDPHASE4

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978

Fuchs DystrophyCataract

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Association Between Fuchs' Endothelial Corneal Dystrophy Severity and Estrogen Exposure

Inclusion Criteria

Exclusion Criteria

FECD-TRACE: Fuchs' Endothelial Corneal Dystrophy TRAjectory and Correlation With Genotype in the United Kingdom

The Evaluation of Balanced Salt Solution During Cataract Surgery

Femtolaser Assisted Keratoplasty Versus Conventional Keratoplasty

Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema